All In Biotech

Drug Trial Radar · NCT06818968

A Study of the Effect of Multiple Doses of Diltiazem on the Plasma Levels of MK-6916 in Healthy Participants (MK-6916-005)

A 2-period, Fixed-sequence, Open-label Study to Evaluate the Effect of Multiple Oral Doses of Diltiazem on the Single-dose Pharmacokinetics of MK-6916 in Healthy Participants

Last checked: Nov 19, 2026Latest source record: Aug 26, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

37

Actual

Start

Feb 27, 2025

Primary completion

Aug 8, 2025

Study completion Aug 8, 2025

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Feb 11, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The goal of the study is to learn what happens to levels of MK-6916 in a healthy person's body over time. Researchers will compare what happens to MK-6916 in the body when it is given with or without another medicine called diltiazem.

Conditions

  • Healthy

Interventions

  • MK-6916Drug

    Oral administration

  • DiltiazemDrug

    Oral administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Area Under the Concentration-Time Curve from Time 0 to Infinity (AUC0-Inf) of MK-6916Time frame: Predose and at designated time points (up to 8 weeks)
  2. Area Under the Concentration-Time Curve from Time 0 to 24 hours (AUC0-24hrs) of MK-6916Time frame: Predose and at designated time points (up to 24 hours)
  3. Plasma Concentration at 24 Hours (C24) of MK-6916Time frame: Predose and at designated time points (up to 24 hours)
  4. Plasma Concentration at 12 Hours (C12) of MK-6916Time frame: Predose and at designated time points (up to 12 hours)
  5. Maximum Plasma Concentration (Cmax) of MK-6916Time frame: Predose and at designated time points (up to 8 weeks)
  6. Time to Maximum Plasma Concentration (Tmax) of MK-6916Time frame: Predose and at designated time points (up to 8 weeks)
  7. Apparent Clearance (CL/F) of MK-6916Time frame: Predose and at designated time points (up to 8 weeks)
  8. Apparent Volume of Distribution (Vz/F) of MK-6916Time frame: Predose and at designated time points (up to 8 weeks)
  9. Apparent Terminal Half-life (t1/2) of MK-6916Time frame: Predose and at designated time points (up to 8 weeks)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Fortrea CRU, Madison ( Site 0001)

    Madison, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.